AbbVie: FDA approval in Parkinson's disease

(CercleFinance.com) - AbbVie announces that the US FDA has approved Vyalev as the first and only 24-hour subcutaneous infusion of a levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
NB: pmt almost flat.

This approval is supported by a 12-week Phase III study, which showed in adults treated with Vyalev a superior improvement in activation time without bothersome dyskinesia, compared to immediate-release oral carbidopa/levodopa.

Affecting more than 10 million people worldwide, Parkinson's disease causes tremors, muscular rigidity, slowness of movement and balance difficulties resulting from the loss of dopamine-producing brain cells.


Copyright (c) 2024 CercleFinance.com. All rights reserved.